|Bid||0.50 x 800|
|Ask||0.51 x 800|
|Day's Range||0.5000 - 0.5200|
|52 Week Range||0.4200 - 2.8700|
|Beta (3Y Monthly)||0.89|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 1, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.60|
NEW YORK, Nov. 06, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
ConforMIS (CFMS) delivered earnings and revenue surprises of 40.00% and 50.92%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Billerica, Massachusetts-based company said it had a loss of 12 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
BILLERICA, Mass., Oct. 31, 2018 -- Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop,.
ConforMIS (CFMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Conformis Inc (NASDAQ:CFMS), a US$58m small-cap, is a healthcare company operating in an industry, which continues to be affected by the sustained economic uncertainty and structural trends, such as an Read More...
BILLERICA, Mass., Sept. 17, 2018-- Conformis, Inc., a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants ...
Two important questions to ask before you buy Conformis Inc (NASDAQ:CFMS) is, how it makes money and how it spends its cash. This difference directly flows down to how muchRead More...
The Billerica, Massachusetts-based company said it had a loss of 24 cents per share. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Zacks.com featured highlights include: Hilton Grand, Fastenal, Catalyst Biosciences, OpGen and ConforMIS
Generally, investors love stocks with a low price-to-earnings (P/E) ratio. The idea is that the lower the P/E, the higher will be the value of the stock. The simple logic that a stock’s current market price does not validate (is not equivalent to) its higher earnings and therefore has room to run justifies investors’ inclination toward low P/E stocks.Source: ©iStock.com/CharlieAJA
On Friday, July 20, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration last Friday's market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: IsoRay Inc. (NYSE AMER: ISR), STAAR Surgical Co. (NASDAQ: STAA), Conformis Inc. (NASDAQ: CFMS), and Integra LifeSciences Holdings Corp. (NASDAQ: IART).
Conformis Inc’s (NASDAQ:CFMS): ConforMIS, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The US$76.75m market-cap company’s loss lessens since it announced a -US$53.58m bottom-line in theRead More...
For today, WallStEquities.com assesses the recent performance of Conformis Inc. (NASDAQ: CFMS), DENTSPLY SIRONA Inc. (NASDAQ: XRAY), Illumina Inc. (NASDAQ: ILMN), and Integra LifeSciences Holdings Corp. (NASDAQ: IART). Companies in the Medical Instruments and Supplies manufacturing industry primarily research, develop, and produce non-electronic medical, surgical, dental, and veterinary instruments and apparatus.